Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Amgen's Prolia Goes, So Goes The Market: Reaction To AC Recs

Executive Summary

FDA and the Reproductive Health Drugs Advisory Committee's focus on small imbalances in Amgen's trial data for Prolia (denosumab) sparked disparate reactions on the Street, with some analysts trimming their estimates and others holding tight

You may also be interested in...

FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow

Denosumab will be indicated for use in postmenopausal women with osteoporosis who are at high risk for fractures.

Amgen Perfectly Positioned To Deal With Prolia Complete Response Letter; Quick Turn-Around Expected

FDA handed Amgen a complete response letter for Prolia, but the company has an armamentarium for handling the agency's requests.

Amgen, FDA Ready For Another REMS Go Around With Prolia

Amgen brings a key commercial advantage to negotiations with FDA over a REMS plan for its osteoporosis drug denosumab: regulatory experience

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts